UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement

Blagden, SP; Billingham, L; Brown, LC; Buckland, SW; Cooper, AM; Ellis, S; Fisher, W; ... Experimental Cancer Medicine Centres (ECMC) CID trials working g; + view all (2020) Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement. British Journal of Cancer 10.1038/s41416-019-0653-9. (In press). Green open access

[thumbnail of s41416-019-0653-9.pdf]
Preview
Text
s41416-019-0653-9.pdf - Published Version

Download (608kB) | Preview

Abstract

The traditional cancer drug development pathway is increasingly being superseded by trials that address multiple clinical questions. These are collectively termed Complex Innovative Design (CID) trials. CID trials not only assess the safety and toxicity of novel anticancer medicines but also their efficacy in biomarker-selected patients, specific cancer cohorts or in combination with other agents. They can be adapted to include new cohorts and test additional agents within a single protocol. Whilst CID trials can speed up the traditional route to drug licencing, they can be challenging to design, conduct and interpret. The Experimental Cancer Medicine Centres (ECMC) network, funded by the National Institute for Health Research (NIHR), Cancer Research UK (CRUK) and the Health Boards of Wales, Northern Ireland and Scotland, formed a working group with relevant stakeholders from clinical trials units, the pharmaceutical industry, funding bodies, regulators and patients to identify the main challenges of CID trials. The working group generated ten consensus recommendations. These aim to improve the conduct, quality and acceptability of oncology CID trials in clinical research and, importantly, to expedite the process by which effective treatments can reach cancer patients.

Type: Article
Title: Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/s41416-019-0653-9
Publisher version: https://doi.org/10.1038/s41416-019-0653-9
Language: English
Additional information: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Keywords: Adaptive clinical trial, Drug development
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10089496
Downloads since deposit
51Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item